Nilotinib Al

Nilotinib, the active ingredient in Nilotinib Al, is a tyrosine kinase inhibitor presented as an oral tablet for oral use. It is indicated for the treatment of chronic myeloid leukemia in adult patients and works by targeting molecular pathways that drive malignant cell growth, offering a targeted therapy option for this hematologic malignancy.

GNH USA supplies Nilotinib Al as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide, adhering to stringent quality standards and providing reliable logistics to ensure product integrity across global markets.

Nilotinib is a targeted therapy used in the management of chronic myeloid leukemia and its disease phases.

- Chronic phase CML: reduces leukemic cell proliferation and improves hematologic response. - Accelerated phase CML: helps achieve cytogenetic and molecular remission. - Blast phase CML: used as part of combination regimens to control aggressive disease.

Adverse reactions to nilotinib may vary in frequency and severity.

Common Side Effects: - Nausea: mild to moderate gastrointestinal upset. - Diarrhea: loose stools that may require hydration. - Rash: skin irritation or erythema. - Fatigue: generalized tiredness. - Headache: mild to moderate head pain. - Myalgia: muscle aches.

Serious or Rare Side Effects: - QT interval prolongation: risk of cardiac arrhythmia. - Pancreatitis: inflammation of the pancreas. - Hepatic toxicity: elevated liver enzymes or hepatitis. - Severe neutropenia: marked reduction in neutrophil count. - Thrombocytopenia: low platelet levels increasing bleeding risk. - Severe skin reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis.

When prescribing nilotinib, clinicians should observe several safety measures.

- Monitor cardiac function: obtain baseline ECG and repeat periodically. - Assess liver enzymes: check hepatic function before and during therapy. - Check blood counts: monitor for neutropenia, thrombocytopenia, and anemia. - Avoid concomitant QT‑prolonging drugs: reduce risk of arrhythmia. - Store at room temperature: keep in the original pack, protect from moisture and light.

Nilotinib may interact with other medicines, requiring careful management.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole): increase nilotinib exposure. - Antacids containing aluminum or magnesium: reduce nilotinib absorption. - QT‑prolonging agents (e.g., sotalol): additive risk of cardiac arrhythmia.

Moderate Interactions (Monitor Closely): - CYP3A4 inducers (e.g., rifampin): decrease nilotinib plasma levels. - Warfarin: may require INR monitoring and dose adjustment.